overweight and or obesity
Obesity research has been transformed by the GLP-1 receptor agonist class (semaglutide, tirzepatide), which achieves 15–22% body weight reduction — approaching surgical outcomes — and reduces cardiovascular events in overweight adults. The pipeline now includes amylin analogs, glucose-dependent insulinotropic polypeptide (GIP) agonists, and oral small molecules targeting appetite regulation.
Active trials investigate next-generation GLP-1 combinations, bimagrumab (anti-ActRII for muscle-sparing weight loss), retatrutide, cagrilintide combinations, and gut microbiome modulators. Trials also study weight regain prevention after GLP-1 discontinuation β€” an emerging clinical challenge.
Obesity trials typically require a BMI ≥30 or ≥27 with weight-related comorbidities; prior bariatric surgery often excludes participants.
Disease Burden & Epidemiology
Obesity is one of the fastest-growing chronic health conditions globally. The World Health Organization estimated that 1 billion people worldwide were living with obesity in 2022 — a figure that has nearly tripled since 1975. In the United States, the CDC reports that 41.9% of adults are obese (BMI ≥30) and an additional 31.1% are overweight (BMI 25–29.9), meaning nearly three-quarters of American adults carry excess body weight. Among children aged 2–19, obesity prevalence stands at 19.7%, representing approximately 14.7 million young people. Obesity is causally associated with type 2 diabetes, hypertension, dyslipidemia, non-alcoholic steatohepatitis (MASH), sleep apnea, osteoarthritis, and at least 13 forms of cancer. The direct medical costs of obesity in the US are estimated at $173 billion per year. The dramatic clinical success of GLP-1 receptor agonists in randomized controlled trials — with the SURMOUNT-1 trial showing 22.5% weight reduction with tirzepatide — has fundamentally shifted the treatment paradigm, validating obesity as a manageable biological disease rather than a behavioral failure and triggering unprecedented investment in the obesity drug development pipeline.
Key Research Trends & Landmark Studies
The STEP 1 trial established semaglutide 2.4mg (Wegovy) as producing 14.9% mean body weight reduction versus 2.4% for placebo in adults with obesity β€” a result that led to FDA approval for chronic weight management in 2021, the first new obesity drug approval in nearly a decade. The SURMOUNT-1 trial subsequently demonstrated that tirzepatide (dual GIP/GLP-1 agonist, Zepbound) achieved even greater efficacy β€” up to 22.5% weight loss in the highest dose group β€” with FDA approval granted in 2023. Crucially, the SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events (MACE) by 20% in overweight/obese adults without diabetes, establishing that the benefit extends beyond glycemic control to hard cardiovascular endpoints. Active trials include the ATTAIN series for cagrilintide/semaglutide (CagriSema) combinations targeting 25%+ weight loss, maridebart cafraglutide (amylin/GLP-1 dual agonist), and orforglipron β€” an oral GLP-1 agonist that removes the injection barrier. Weight regain prevention and lean mass preservation are emerging primary endpoints as the field matures.
Patient Guide: How to Find & Join a Trial
Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition — type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease — are broadly eligible for most obesity clinical trials. Before screening, document your current BMI, weight history over the past year, any prior obesity treatments (including prior GLP-1 use, which may be an exclusion), and your complete list of comorbidities with current medications. Obesity trials are among the most geographically accessible in clinical research: many are conducted at community endocrinology and primary care practices rather than exclusively at academic centers, and decentralized elements (home weight monitoring, remote visits) are increasingly standard. Patients currently on GLP-1 therapy who are seeking access to next-generation agents may qualify for switch trials comparing newer compounds to established treatments.